The FDA webpage in question is not a document announcing new drug supply chain regulations, but rather a standing preparedness page guiding the storage and safe use of drugs before and after natural disasters. It emphasizes that drugs exposed to flooding, fire, power outages, or refrigeration failures may be contaminated or have reduced efficacy, even if they appear normal, and should be checked by a professional before use. Therefore, the core issue is not new drug approvals or clinical trials, but the operational risks that natural disasters pose to the quality and continuity of supply for marketed essential medicines.

The Hurricane Helen incident revealed a single-point-of-failure risk. In September 2024, Hurricane Helen caused flooding that shut down Baxter International's (BAX) facility in North Carolina. This facility produced approximately 1.5 million of the 2.5 million intravenous solution bags used daily in the United States, representing 60% of the total supply and becoming a single point of failure in the hospital supply chain. Affected marketed products included 0.9% sodium chloride injection, dextrose injection, lactated Ringer's solution, and Dianeal dextrose and Extraneal icodextrin peritoneal dialysis solutions. These are essential treatments that maintain fluid, sodium, chloride, and glucose balance, or the osmotic gradient of the peritoneum.

The FDA's actual regulatory response involved the FDA officially acknowledging the shortage of 70% dextrose injection, lactated Ringer's solution, and peritoneal dialysis solutions on October 11, 2024, and issuing an immediately effective guidance allowing for the compounding of certain non-sterile products. This is an enforcement discretion measure to reduce supply gaps through temporary compounding by 503A pharmacies and 503B outsourcing facilities, rather than an emergency use authorization (EUA) or product approval, or an AdComm review. The FDA also facilitated the temporary import of products from Baxter's overseas facilities, allocation management, and supply preservation, and the North Carolina facility resumed shipping new products within approximately 60 days. Separately, the 2022 draft Risk Management Plan (RMP) to mitigate supply shortages is a non-binding recommendation and, as previously stated, is not a guidance that imposes new binding obligations on all manufacturers.

Market and corporate value impact: Research and Markets valued the global intravenous solution market at USD 13.9 billion in 2024, with key suppliers including Baxter, B. Braun Melsungen, Fresenius Kabi, and ICU Medical (ICUI). Baxter initially projected a USD 200 million decrease in fourth-quarter 2024 revenue and USD 350-400 million in costs, but the actual net cost, after insurance recovery of USD 251 million, was USD 110 million, as reflected in the annual report. The impact on Medical Products & Therapies operating income was USD 60 million, and Baxter's total revenue for 2024 was USD 10.64 billion. Redundancy in production sites and regional alternative sourcing capabilities have evolved beyond cost items to become competitive assets that determine hospital contract retention and valuation.